Cue Biopharma (CUE) Equity Average (2018 - 2025)

Cue Biopharma has disclosed Equity Average across 8 years of filings, most recently posting $19.8 million for Q4 2025.

• Equity Average for Q4 2025 came in at $19.8 million, down 7.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.8 million (down 7.43% YoY), and the FY2025 annual result was $22.0 million, down 19.52% from the prior year.
• Equity Average came in at $19.8 million for Q4 2025 at Cue Biopharma, up from $15.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $74.3 million in Q1 2021 to a low of $12.0 million in Q1 2025.
• The 5-year median for Equity Average is $47.4 million (2023), against an average of $43.9 million.
• Across the five-year window, Equity Average surged 48.85% in 2021 and tumbled 64.13% in 2025, its largest moves.
• Cue Biopharma's Equity Average stood at $64.5 million in 2021, then decreased by 9.74% to $58.2 million in 2022, then plunged by 31.51% to $39.9 million in 2023, then tumbled by 46.25% to $21.4 million in 2024, then retreated by 7.43% to $19.8 million in 2025.
• The last three Equity Average figures came in at $19.8 million (Q4 2025), $15.7 million (Q3 2025), and $12.4 million (Q2 2025), per Business Quant data.